Format

Send to

Choose Destination
Biochem Pharmacol. 2016 Dec 15;122:33-41. doi: 10.1016/j.bcp.2016.09.019. Epub 2016 Sep 21.

Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.

Author information

1
Systems Biology Department, Universidad de Alcalá and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Alcalá de Henares, Spain.
2
Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and CIBEREHD, Madrid, Spain.
3
Hospital de Fuenlabrada, Madrid, Spain.
4
Hospital la Fe, Valencia and CIBEREHD, Spain.
5
Hospital de Galdakano, Vizcaya, Spain.
6
Hospital de Donostia, Guipúzcoa, Instituto Biodonostia, UPV/EHU and CIBEREHD, Spain.
7
Hospital Clínico San Carlos, and IdISSC, Madrid, Spain.
8
Hospital Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba, Universidad de Córdoba, Córdoba, Spain.
9
Hospital Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
10
Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
11
Hospital Universitario Puerta de Hierro, Madrid, Spain.
12
Hospital Universitario la Paz, Madrid, Spain.
13
Hospital Universitario Ramón y Cajal, Madrid, Spain.
14
Hospital General de Alicante, Alicante, Spain.
15
Hospital Clínico Universitario "Lozano Blesa", IIS Aragón, Zaragoza and CIBEREHD, Spain.
16
Hospital de Manises, Valencia, Spain.
17
Systems Biology Department, Universidad de Alcalá and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Alcalá de Henares, Spain. Electronic address: luis.gonzalez@uah.es.

Abstract

BACKGROUND:

The availability of a quantitative method to measure anti-infliximab (IFX) antibodies (ATI) would facilitate the implementation of therapeutic drug monitoring in clinical decision-making. Our aim was to standardize the homogeneous mobility shift assay (HMSA) used in the measure of ATI levels.

METHODS:

In this prospective longitudinal multicenter study, 50 IFX-treated Crohn's disease (CD) patients were followed up for 54weeks. During this period 360 human serum samples were analysed. Monomeric ATI levels were measured by a quantitative HMSA-method using an anti-IFX calibrator. IFX trough levels measured by ELISA were correlated with ATI levels.

RESULTS:

Using HMSA and a pure anti-idiotypic monoclonal antibody specific for IFX (anti-IFX calibrator), we measured the levels of monomeric ATI generated in Crohn's disease patients treated with IFX. Anti-IFX calibrator allowed to quantify monomeric antibodies against IFX with a low limit of quantification (3nM). The threshold level of ATI in order to classify the immunogenicity of the patients was 10nM. We observed that 24% (12/50) of IFX-treated patients developed ATI (>10nM) during the observation period (54weeks). Serum concentration of ATI higher than 10nM dramatically increased the probability (OR=51.1; 95% CI: 20.4-128.0; p<0.0001) of presenting low levels of IFX (⩽1.5nM) in serum, as observed in some CD patients treated with standard doses of the drug.

CONCLUSIONS:

The HMSA-method described here allows an accurate quantification of ATI concentration in international units (IU) and therefore it could be useful in the study of the relationship between ATI concentration, infliximab level and the clinical response to the drug.

KEYWORDS:

Anti-drug antibodies; Crohn’s disease; HMSA; Infliximab

PMID:
27664854
DOI:
10.1016/j.bcp.2016.09.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center